ZyVersa: Preclinical Data Supports Potential Of IC 100 Against Alzheimer's, Parkinsons

(RTTNews) - ZyVersa Therapeutics (ZVSA) said newly published data has demonstrated that NLRP3 Inhibition attenuates development of Alzheimers disease pathology and neuroinflammation in a mouse model of AD, thereby attenuating disease progression. The new study data were published in the peer-reviewed journal, Immunity. In the publication, the researchers reported data from studies conducted in a mouse model of Alzheimers disease, murine microglia, and human THP-1 cells. The company noted that these data support the potential of ZyVersa's Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with neurodegenerative diseases such as Alzheimer's and Parkinsons diseases.

"These data strengthen support for the potential role for Inflammasome ASC Inhibitor as a treatment for Alzheimers and other neurological diseases, such as Parkinsons disease," said Stephen Glover, ZyVersas Co-founder, Chairman, CEO and President.

Shares of ZyVersa Therapeutics are up 13% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.